8,015 Shares in CVS Health Corporation $CVS Acquired by Stableford Capital II LLC

Stableford Capital II LLC purchased a new position in shares of CVS Health Corporation (NYSE:CVS) during the third quarter, Holdings Channel.com reports. The fund purchased 8,015 shares of the pharmacy operator’s stock, valued at approximately $687,000.

Other hedge funds have also made changes to their positions in the company. Mn Services Vermogensbeheer B.V. boosted its position in CVS Health by 1.3% during the 3rd quarter. Mn Services Vermogensbeheer B.V. now owns 375,568 shares of the pharmacy operator’s stock valued at $32,182,000 after purchasing an additional 4,900 shares during the period. Farther Finance Advisors LLC increased its position in CVS Health by 30.6% in the third quarter. Farther Finance Advisors LLC now owns 54,244 shares of the pharmacy operator’s stock worth $4,648,000 after buying an additional 12,718 shares during the period. CoreCap Advisors LLC lifted its stake in CVS Health by 50.6% in the third quarter. CoreCap Advisors LLC now owns 5,242 shares of the pharmacy operator’s stock valued at $449,000 after buying an additional 1,761 shares during the last quarter. Artemis Investment Management LLP boosted its holdings in shares of CVS Health by 65.6% during the third quarter. Artemis Investment Management LLP now owns 50,481 shares of the pharmacy operator’s stock valued at $4,326,000 after acquiring an additional 20,000 shares during the period. Finally, Hamlin Capital Management LLC grew its position in shares of CVS Health by 13.6% during the third quarter. Hamlin Capital Management LLC now owns 1,951,402 shares of the pharmacy operator’s stock worth $167,216,000 after acquiring an additional 233,794 shares during the last quarter. Institutional investors own 80.66% of the company’s stock.

CVS Health News Summary

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Aetna’s Medicare Advantage quality ratings are a key positive. More than 69% of Aetna’s Medicare Advantage members are enrolled in plans rated four stars or higher for 2027. Strong CMS Star Ratings could support member retention, enrollment and Medicare Advantage economics, making this the most significant near-term catalyst. Aetna 2027 Star Ratings Reflect Strong Clinical Quality and Member Experience
• Positive Sentiment: Investors are positioning for further gains. Traders purchased about 23,271 CVS call options, roughly 33% above typical call volume. This signals increased bullish speculation, although options activity is not a guarantee of sustained share-price appreciation. Traders Buy Large Volume of Call Options on CVS Health
• Positive Sentiment: Long-term pharmacy operations gained greater supply-chain visibility. CVS extended pharmaceutical distribution agreements with Cardinal Health and McKesson through 2032, supporting continuity for its nationwide retail pharmacy network. The company is also expanding access through a pharmacy-focused Boston location.
• Neutral Sentiment: Analysts see potential recovery, but the valuation case remains execution-dependent. Commentary points to recovering Aetna margins, improving pharmacy trends and momentum in CVS Health Services. CVS trades at a discount to industry peers, but investors are watching whether its integrated-care strategy can translate into durable earnings growth.
• Negative Sentiment: 340B pricing pressure remains a headwind. Persistent challenges from the federal 340B drug-pricing program could weigh on pharmacy profitability and offset some of the gains from improved insurance and health-services performance.

CVS Health Stock Performance

CVS stock opened at $87.91 on Friday. The company has a 50-day simple moving average of $93.10 and a 200 day simple moving average of $92.41. The company has a market capitalization of $112.43 billion, a P/E ratio of 23.26, a PEG ratio of 0.82 and a beta of 0.60. The company has a quick ratio of 0.66, a current ratio of 0.87 and a debt-to-equity ratio of 0.74. CVS Health Corporation has a fifty-two week low of $69.51 and a fifty-two week high of $110.68.

CVS Health (NYSE:CVS) last released its earnings results on Wednesday, August 5th. The pharmacy operator reported $2.58 EPS for the quarter, beating the consensus estimate of $1.87 by $0.71. CVS Health had a net margin of 1.18% and a return on equity of 13.12%. The firm had revenue of $106.10 billion for the quarter, compared to analysts’ expectations of $100.03 billion. During the same quarter last year, the company earned $1.81 EPS. CVS Health’s quarterly revenue was up 7.3% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. Sell-side analysts predict that CVS Health Corporation will post 8.02 earnings per share for the current fiscal year.

CVS Health Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 2nd. Investors of record on Thursday, October 22nd will be paid a dividend of $0.6650 per share. This represents a $2.66 dividend on an annualized basis and a dividend yield of 3.0%. The ex-dividend date is Thursday, October 22nd. CVS Health’s dividend payout ratio (DPR) is currently 70.37%.

Wall Street Analyst Weigh In

Several analysts recently weighed in on CVS shares. Royal Bank Of Canada lifted their price objective on shares of CVS Health from $107.00 to $113.00 and gave the company an “outperform” rating in a research report on Thursday, July 9th. Piper Sandler set a $112.00 target price on shares of CVS Health in a research report on Wednesday, September 9th. UBS Group restated a “buy” rating on shares of CVS Health in a research note on Tuesday, September 22nd. HSBC reaffirmed a “hold” rating and set a $103.00 price target on shares of CVS Health in a report on Monday, July 6th. Finally, JPMorgan Chase & Co. increased their price objective on CVS Health from $111.00 to $118.00 and gave the stock an “overweight” rating in a report on Wednesday, August 12th. Twenty-two research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, CVS Health presently has a consensus rating of “Moderate Buy” and an average price target of $107.24.

CVS Health Company Profile

CVS Health Corp. is an integrated health care company that provides pharmacy, insurance and health services primarily in the United States. Its operations are designed to connect consumers, health plans, health care providers and pharmacy services across multiple points of care.

The company’s major businesses include CVS Pharmacy retail locations, prescription fulfillment and consumer health products; CVS Caremark, a pharmacy benefit management business; and Aetna, which offers health insurance products and related services for employers, individuals, government programs and other organizations.